OXFORD, UK and SALT LAKE CITY, UT – 26 February 2025 – PrecisionLife and Metrodora Foundation have announced the successful reproduction of the genetic risk factors associated with long COVID across US and UK patient populations with diverse ancestries. The landmark study, leveraging PrecisionLife’s unique combinatorial analytics platform, represents a significant step forward in understanding the genetic underpinnings of long COVID and offers a strong foundation for the development of more precise diagnostic tools and therapeutic strategies, pending further clinical validation.
Long COVID is a complex, long-term debilitating condition that affects tens of millions of patients, creating a rising healthcare and lost productivity burden of over $1 trillion (or 1% of global GDP) annually1. However, traditional genome-wide association studies (GWAS) have struggled to identify any reproducible genetic associations, limiting progress in studying the condition. Understanding the specific biological causes of disease in different patients is essential for developing effective diagnostics and personalized treatments.
In a rigorous study, PrecisionLife analyzed data from the US National Institutes of Health’s All of Us Research Program, to reproduce findings from its previous study2 based on data from the UK Sano GOLD long COVID project. Over 88% of the genes identified in the initial study that could be tested were replicated in the All of Us cohort, despite significant ancestry differences between populations.
The findings will enable a much-needed definition of long COVID diagnosis and pave the way for a biomarker-driven diagnostic test that can accurately evaluate an individual’s genetic risk of developing the condition and distinguish it from other post-viral syndromes to guide personalized prevention and treatment strategies.
A definitive diagnostic test for long COVID will facilitate research, help to prioritize healthcare resources and enable clinicians to rapidly and accurately triage patients, ensuring they receive timely and equitable access to treatment, reducing the cost of delivering healthcare and improving patient lives.
“Confirming that we can reproduce long COVID genetic risk factors across populations with different ancestries is a crucial step forward for understanding the disease,” said Steve Gardner, CEO of PrecisionLife. “These findings redefine our understanding of the genetic components of long COVID, laying the foundation for precision medicine approaches that could revolutionize care for millions. They also provide strong support for the use of combinatorial analytics to find exciting new opportunities for precision diagnostics and the accelerated development of targeted therapeutics in complex, chronic diseases that affect billions of lives.”
The study found that 11 out of 13 drug repurposing targets previously identified by PrecisionLife were also observed in the All of Us dataset, strengthening the case for targeted clinical trials to evaluate their efficacy. These findings suggest that the novel insights generated by combinatorial analysis into the mechanisms of complex conditions can be used to prioritize promising existing drugs for rapid clinical validation.
“Patients with complex conditions, like long COVID, simply can’t wait. They are suffering daily. They need solutions, and they need them now,” said Amy Rochlin, Executive Director of Metrodora Foundation. “We care deeply about getting patients the answers they deserve, and we’re committed to driving progress forward with urgency. By combining PrecisionLife’s powerful AI-driven genetic analysis with diverse patient data, we’re gaining critical insights that may bring us closer to real solutions, with the potential to truly improve patients' lives.”
The research was conducted to support the MetX and MELO studies, flagship clinical programs funded by the Metrodora Foundation and run at the Metrodora Institute. These studies aim to build upon PrecisionLife’s discoveries of the mechanisms underlying chronic diseases into real-world clinical applications, with the goal of informing future clinical applications and improving outcomes for patients suffering from conditions with high unmet medical need.
“These results give us hope and drive to continue this important work, empowering clinicians to provide better care and improve the lives of millions,” said Rohit Gupta, Principal Investigator for the MetX and MELO studies at Metrodora Institute. “We are committed to accelerating the development of diagnostics and treatments through our collaboration with PrecisionLife.”
The study has been submitted for publication and is currently available on medRxiv, the pre-print server for health sciences, here: https://doi.org/10.1101/2025.02.04.25320937.
ENDS
[1] Al-Aly, Z., Davis, H., McCorkell, L. et al. Long COVID science, research and policy. Nat Med 30, 2148–2164 (2024). https://doi.org/10.1038/s41591-024-03173-6.
[2] Taylor, K., Pearson, M., Das, S., Sardell, J., Chocian, K. and Gardner, S., 2023. Genetic risk factors for severe and fatigue dominant long COVID and commonalities with ME/CFS identified by combinatorial analysis. Journal of Translational Medicine, 21(1), p.775. https://doi.org/10.1186/s12967-023-04588-4.
This ongoing study aims to evaluate biomarkers in ME/CFS and long COVID with the goal of creating accurate tests, discovering new and repurposed drug candidates, and improving the understanding of the biological drivers of these conditions. The MELO Study, funded by a generous donation from the Metrodora Foundation, features a collaboration between the Metrodora Institute—with its decentralized platform for patient engagement, specimen collection, and genotyping—and PrecisionLife, which has contributed its unique disease insights, test designs, and repurposing candidates.
To get involved or find out more about the MELO Study visit www.metrodorainstitute.co/melo-study and join the Metrodora Connect research platform through the MyDataHelps app to find out about new studies and clinical trials.
Click here to download the app for iOS.
Click here to download the app for Android.
Use the code BMDSMX when registering to enter Metrodora Connect.
PrecisionLife is a clinical-stage precision medicine company creating better diagnostic tools and more personalized treatment options to predict, treat, and prevent complex chronic diseases, which affect over 5 billion patient lives and account for over 80% of healthcare spending.
The company’s unique AI-led combinatorial analytics platform is unparalleled in its ability to identifyingcausal disease biology – the underlying drivers of many diseases for the first time, linking individuals to the treatments that will benefit them most, and accurately predicting lifetime risk of disease.
PrecisionLife’s precision medicine insights and diagnostic tools hold the key to reducing the global burden of chronic diseases, improving the rate of successful drug development, and increasing healthspan for billions of people.
For more information:
Visit: precisionlife.com
Contact: press@precisionlife.com
Follow: PrecisionLifeAI
Metrodora Foundation is a 501(c)(3) nonprofit organization dedicated to advancing groundbreaking research, clinical innovation, and patient solutions for complex chronic conditions. The Foundation is dedicated to collaborating with top researchers, medical institutions, and industry leaders to accelerate the development of diagnostic tools, targeted therapies, and evidence-based interventions that transform outcomes and improve lives.
Located in Salt Lake City, Utah, the Metrodora Institute was founded in 2021 with the vision of reimagining care and accelerating research to improve the treatment of complex multisystem disorders. Through physician and patient partnerships, Metrodora is uniquely positioned to develop and commercialize new diagnostic tests and therapeutics for those living with these debilitating conditions. Metrodora Institute has created an innovative offering with access to advanced tools and world-class expertise.
Metrodora media inquiries:
Summer Dashe
VP of Marketing and Communications
media@metrodora.co